Literature DB >> 26875574

[The guidelines for the diagnosis and management of multiple myeloma in China (2015 revision) : interpretation of the treatment of relapsing and refractory multiple myeloma].

Wenming Chen.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26875574     DOI： 10.3760/cma.j.issn.0578-1426.2016.02.004

Source DB:  PubMed          Journal:  Zhonghua Nei Ke Za Zhi        ISSN： 0578-1426


× No keyword cloud information.
  2 in total

1.  Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.

Authors:  Wei-Jun Fu; Ya-Fei Wang; Hong-Guo Zhao; Ting Niu; Bai-Jun Fang; Ai-Jun Liao; Hai Bai; Jin Lu
Journal:  BMC Cancer       Date:  2022-07-01       Impact factor: 4.638

2.  The VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis.

Authors:  Gan-Lin He; Duo-Rong Xu; Wai-Yi Zou; Sui-Zhi He; Juan Li
Journal:  Biomed Res Int       Date:  2018-11-11       Impact factor: 3.411
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.